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Abstract
Symptoms of acute Infectious Mononucleosis (IM), which develops after Epstein-Barr virus (EBV) in half the cases, is strikingly like 
those of Hodgkin’s Lymphoma (HL). This, combined with the findings that many patients with HL had a history of EBV and/or IM, 
triggered an interest in scientists to learn if the two were biochemically related. Many studies in this field unanimously concluded 
that the development of IM after EBV infection presented a higher risk of developing HL. However, whether this relationship is 
coincidental or pathological remains a matter of controversy until this day . In the last decade, there has been a lot of research and 
advances in this field. Various studies have looked at the correlation of EBV and HL considering age factors, genetic predispositions, 
and immunity and susceptibility dynamics. Researchers discovered that development of HL after EBV was most prevalent in 
young adults and old patients, pointing to immune system function, or lack thereof . It was also found to be more common in men, 
suggesting that this may be a sex-related disease. Specific genes activated or mutated in both EBV and HL have proposed that 
the development of HL after EBV/IM may be genetically regulated. By tracing geminal centre B cell replication patterns, EBV gene 
expression, and lytic cycle proteins, different mechanisms for the pathogenesis of HL from EBV were proposed. Various studies 
made use of statistics and patients’ medical records to make assumptions. Other methods employed in these studies included 
probe hybridization to extract DNA and RNA samples from tumor specimens, flow cytometry and polymerase chain reactions 
(PCR) to identify genetic sequences, and immunohistochemistry to study antigens specific to EBV and related diseases.
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Introduction
Is there a correlation between Epstein - Barr virus and Hodgkin’s 
Lymphoma? If so, what is the nature of this relationship? The 
objective of this paper is to briefly discuss some studies which 
initially led health professionals to believe that Hodgkin’s lym-
phoma (HL) is caused by EBV. Then, possible causes and mech-
anisms which may lead the viral disease to transform infected 
cells to malignant tumors will be expounded upon.
The lymphatic system is an important regulatory mecha-
nism involved in the immune response of the body. It is com-
prised of lymphatic channels which conduct the lymphatic fluid 
throughout the body and converge regionally to form discreet 
lymph nodes (Freeman and Matto, 2018). The function of the 
lymph node is to evaluate and initiate an immune response 
when necessary. It functions as an antigen filter consisting of 
a multi-layered sinus that successively exposes B-cell lympho-
cytes and T-cell lymphocytes to an afferent extracellular fluid 
(Evans, 1974). B and T lymphocytes are subtypes of white blood 
cells that contribute to the immune system. For example, by 
secreting antibodies, the B cells thus play a central role in im-
munity. In addition, T cells exhibit cell-mediated immunity. In 
the course of an immune response, where foreign proteins 
are recognized and attacked, the immune cell line undergoes 
multiplication, thereby causing the lymph node to increase in 
size. Generalized or localized lymphadenopathy, an abnormality 
in the size or consistency of lymph nodes, is the most common 
feature in lymphoproliferative disorders. These disorders refer 
to potentially fatal conditions in which lymphocytes are pro-
duced in excessive quantities. Included in this broad category of 
disorders, are Epstein-Barr Virus, Infectious Mononucleosis, and 
Hodgkin’s Lymphoma. 
EBV is a tumorigenic double stranded DNA herpesvirus that 
commonly develops in the first decade of life of an individual. 
It infects more than 90% of the human population worldwide 
(Yang, et. al., 2015). EBV consists of the EBV-1 and EBV-2 sub-
types, with EBV-1 being more prevalent in western societies. 
An immune response consisting of natural killer (NK) cells and 
EBV-specific cytotoxic CD8+ T lymphocytes controls the pri-
mary infection and reactivation that occurs in all EBV-positive 
individuals. While EBV is often found in B cells in its latent ep-
isomal form, lifelong persistence of EBV in infected individuals 
involves occasional reactivation to the lytic state, resulting in 
lyses of infected cells and the release of virus particles which 
triggers acute infection (Babcock, et. al., 1998). 
Primary EBV infections in children are usually asymptomatic 
yet can result in infectious mononucleosis (IM) development in 
50% of adolescent patients (Jenson, 1996). It was not until 1968 
that EBV was first associated with IM, followed by further re-
search which ultimately confirmed that EBV was a causative agent 
of IM. Most of the symptoms of infectious mononucleosis are at-
tributed to the proliferation and activation of T cells in response 
to infection. It is characterized by abnormally high numbers of 
circulating CD8+ T cells and B cells. Among its many symptoms, 
lymphadenopathy and lymphocytosis – abnormal numbers 
of lymphocytes in the circulating blood (Sawari, et. al., 2016) - 
acutely resemble HL. In fact, IM is occasionally misdiagnosed as 
Hodgkin’s Lymphoma due to the similarity in their symptoms and 
small biopsy specimens in the Waldeyer’s ring (WR), which may 
be difficult to differentiate (Delecluse, et. al., 2007). This similarity, 
among other factors had led researchers to suspect that one dis-
ease may derive from the alteration of the other.
According to the World Health Organization (WHO), 
Hodgkin’s lymphoma is a disorder characterized by an abnor-
mality in the lymph node’s architecture (Tzankov and Dirnhofer, 
2006). HL, also commonly known as Hodgkin Disease (HD), en-
compasses four histological subtypes, with 40% of sclero-nod-
ular type and 80% of mixed cellularity type carrying the EBV 
virus (Delecluse, et. al., 2007).  It is comprised of characteristic 
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neoplastic cells known as Hodgkin’s Reed-Sternberg (HRS) cells. 
These interspersed cells only constitute approximately 2% of 
the total tumor mass while the rest of the tumor consists of T 
cells, B cells, eosinophils, macrophages, granulocytes, and others 
(Yang, et. al., 2015). The classic Hodgkin Reed–Sternberg cells 
are large cells with two or more round nuclei. The mononuclear 
form is referred to as the Hodgkin cell (Ok, et. al., 2015). HRS 
cells communicate with other cells via cell contact dependent 
interactions, including proliferative and anti-apoptotic signals 
favoring tumor cell survival and expansion. EBV is most com-
monly associated mixed-cellularity subtype, the most common 
type of classical Hodgkin disease. 
Using data from discharge records of patients hospitalized for 
Hodgkin’s Lymphoma and/or Infectious Mononucleosis, studies 
were performed by compiling the prevalence of the disorder 
relating to age and gender. Tracking the medical history of these 
patients allowed for the determination of how many patients 
with HL have a past history of EBV/IM. B and T lymphocytes in 
blood of patients with Hodgkin’s disease, infectious mononucle-
osis, and normal controls were collected and compared. Due 
to the rarity of EBV-infected B cells in healthy virus carriers, it 
is complicated to analyze them directly (Caldwell, et. al., 1998). 
To resolve this issue, Thorley-Lawson developed a method in 
which human B cells are separated via flow cytometry, which 
works by suspending cells in a fluid and passing them through 
an electronic detector. Then, using polymerase chain reaction 
(PCR), cells are analyzed for the presence of EBV infection. 
Additionally, using, viral DNA and RNA segments from tumor 
specimens were extracted and studied via southern blot hy-
bridization with probes specific for parts of the EBV genome. 
Reverse transcriptase of RNA can also be used to identify the 
genetic sequence of specific genes (Khan, et. al., 1996). Epstein-
Barr virus’ early RNA transcripts were detected in tumor tis-
sues, via fluorescein-labeled oligonucleotides complementary to 
the RNA sequence. The fragments were then visualized under a 
microscope by tetramethyl rhodamine isothiocyanate (TRITC), 
a bright orange-fluorescent dye. Other studies have applied 
immunohistochemistry techniques, the detection of antigens in 
cells of a tissue by introducing antibodies binding specifically to 
these proteins. Finally, experiments with transgenic mice were 
useful for studying genes. Control and experimental groups of 
mice were infected with either wild type (WT) or knockout 
(KO) genes to see how they affect the course of the disease. 
Discussion
It is generally held that a lymph node is considered enlarged when 
it is larger than 1 cm, however, this can vary depending on the loca-
tion of the node and the age of the patient (Cheng and O’Connor, 
2017). Patients with a diagnosis of EBV, IM, and HD presenting with 
lymphadenopathy, were studied. The goal was to determine if and 
how these diseases are correlated. Different propositions as to 
the nature of their relationship have been reviewed.  
Using data from the Oxford Record Linkage Study (ORLS), 
a cohort of 2797 patients admitted to the hospital with an 
International Classification of Diseases (ICD) code for infec-
tious mononucleosis on the discharge record were studied. 
Patients studied were mostly ages <20-30 at the time of admis-
sion. Admission was substantially more common in males than 
in females. Those with a diagnosis of cancer either before or at 
the same time as admission for IM were excluded. Tracking the 
medical records of these patients showed an increased risk for 
the development of HD with a relatively short follow up period 
ranging from 1-7 years post discharge (Goldacre, et. al., 2008). 
A similar study looked at 233 cases of HL in children recorded 
between 1957 and 2001. Reliable data concerning the onset of 
symptoms was available in 172 cases, and in 31 of these patients, 
EBV status was unknown. Of the 141 tumors, 69 (48.9%) were 
EBV-positive (Reiman, et. al., 2003). In another unrelated cohort 
study on young adults, it was indicated that individuals who had 
a history of IM were three times more likely to develop HL 
(Jarrett, 2003). The incubation period of infectious mononucle-
osis after EBV was observed to be between 32 and 49 days. 
(Balfour, et. al., 2015). The follow up period between EBV and HL 
varied with different genders, ethnic groups, and age.
Both IM and HL typically develops in adolescence and early 
adult life. In fact, the development of IM after EBV is now con-
sidered to be a risk factor for Hodgkin’s disease. However, the 
nature of this association remains unclear. Examining blood 
samples from patients with HD, showed EBV latency in B cells. 
However, it must be noted that not all subtypes of HL harbor 
EBV to the same degree. Some data suggests that the incidence 
of EBV-positive HL may be age-related. The observed age-in-
cidence pattern suggests that risk of HD is increased among 
younger people, with a peak in incidence at 25 to 30 years and a 
second rise after the age of 45 (Khanna, et. al. 1995). An increase 
in the severity of infection in young patients leads to the devel-
opment of cancer. In one study, a similar pattern was recorded 
among aging patients suggesting that the immunologic status of 
the patient plays a crucial role in the subsequent development 
of pathologies (Mueller, 1987). Dr. Evans proposed that perhaps 
HD represent the host’s response to an EBV infection that is 
delayed until adolescence/early adulthood (1974). Another plau-
sible explanation would be that HD develops as a secondary 
response in patients with genetic susceptibility, low immunity, 
or a combination of both. 
A study was done in which a samples of B and T lymphocytes 
in patients with HD, IM, and a normal control were analyzed. They 
then compared the results of each group to the others. In over-
all counts, the number of T lymphocytes significantly exceeded 
that of B cells. However, while in infectious mononucleosis the 
count of T-lymphocytes was elevated, there was a slight reduction 
in Hodgkin’s Disease. It was also observed that in patients with 
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HD there was an increase in the number of DNA synthesizing 
lymphocytes was found when compared to normal controls. The 
ability of the disease to persist despite potential immune respons-
es against it indicates that the virus has invented pathways to 
evade the immune system. Also, untreated patients differed from 
their treated peers in their absolute lymphocyte counts; treated 
patients presented with a lower number of DNA-synthesizing 
blood lymphocytes. Cells observed in the blood of patients with 
Hodgkin’s disease and infectious mononucleosis were indistin-
guishable. Based on these findings, it was inferred that trans-
formed lymphocytes represent normal lymphocytes that have 
undergone a proliferative response signaled by tumor surface 
antigens or viral infections (Huber et. al.1975).
EBV-associated lymphoproliferative disorders (LPDs) are 
life-threatening diseases commonly found in those with a com-
promised immune system, especially children. T-cell dysfunction 
can cause development of mature B-cell lymphoma by impairing 
immune function. Additionally, a partial lytic infection plays a role 
in EBV-induced B-cell tumors. Although the main targets of EBV 
are B cells, EBV may also infect other cells, such as T cells and 
epithelial cells (Rickinson and Kieff, 2001). 
Once infected, EBV persists in rare peripheral blood lympho-
cytes for the rest of the host’s life, usually as a harmless passenger 
residing in B cells (Ohashi, et. al., 2012). Since there is limited viral 
protein expression in the latent form, EBV reduces the number 
of viral proteins that permit the recognition of infected cells by 
cytotoxic T cells. During its reactivation, which takes place during 
the lytic life cycle, memory B cells are activated and differentiate 
into plasma cells. People who have EBV can transmit the disease 
through oral secretions because the virus replicates in cells in 
the oropharynx. Generally, the number of infected lymphocytes is 
stable over time. However, in rare instances, infection of epithelial 
cells by EBV in vitro results in active replication, and consequently, 
lysis of the cell which spreads the virus to other cells (Cohen, 
2000). Although the primary site of virus replication is in the 
pharyngeal epithelium, circulating B lymphocytes can become in-
fected too, thereby generalizing the infection. In B cells, persistent 
infection can transform the cell, which may result in the develop-
ment of malignant lymphomas, especially Hodgkin lymphoma. Like 
all herpes viruses, EBV has latent and productive (lytic) phases in 
its life cycle (Niedobitek, et. al., 2001). Therefore, EBV establishes 
a life-long infection in individuals which is generally harmless un-
less the host–virus balance is upset. The latent genes which keep 
the virus in the host’s B lymphocytes induce immortalization and 
oncogenic potential too. EBV differs from other herpes viruses 
though in its capacity to transform B cells. Latent infection of B 
cells by EBV in vitro can result in a transformation to lympho-
blastoid cells, thereby leading to immortalization of the cells. In 
fact, the International Agency for Research on Cancer classified 
EBV as a group 1 carcinogen.
In more recent years, studies of tissue cultures of Epstein-Barr 
virus growth in peripheral blood lymphocytes has shed some 
light on the molecular events associated with B cell growth 
transformation and virus replication (Ohashi, et. al., 2012). Studies 
have shown that the main type of EBV-associated B-cell lym-
phoma — that is, Hodgkin lymphoma— seems to derive from 
germinal-Centre B cells, a structure found in lymphoid tissues 
that is composed of proliferating B cells. This indicates that EBV-
infected germinal-Centre B cells are at the greatest risk for ma-
lignant transformation (Küppers, 2003). After B cells are infected, 
virus–receptor interaction induces activation of the infected cells 
which enter the mitotic cycle, leading to lymphoblastoid cell lines 
(LCLs). LCL has the phenotype of an activated B-blast, expressing 
activation, adhesion, and anti-apoptosis proteins. Since lympho-
blasts resemble activated B cells both in their phenotype and 
molecular features, the virus is thought to push infected naive B 
cells into the memory state by switching the cell from the growth 
program to the default program. Normally, the latently infected 
memory cells shut down the viral expression entering the latent 
state. However, when the latently infected memory cells divide, 
they express the EBNA-1 protein causing the viral DNA to rep-
licate. Ultimately, the latent virus is reactivated and proliferates, 
spreading to other hosts. It is therefore derived that the virus can 
remain latent in the memory cells for long periods of time with-
out causing any harm to the host. A risk arises if memory cells 
are accidentally triggered into expressing the growth program 
(Thorley-Lawson and Gross, 2004).
In germinal centre B cells, a more restricted EBV gene ex-
pression pattern is detected in which only EBNA1, LMP1 and 
LMP2A proteins are expressed (Bancock, et. al., 2000). Also, 
in the germinal centre expansion causes the number of EBV-
infected B cells to increase. These germinal centre B cells then 
differentiate into memory B cells, which are the long-term la-
tent form of EBV (Babcock, et. al., 1998). In EBV-associated HL, 
viral genomes were found in their monoclonal form, indicating 
that infection of the tumor cells occurred prior to their un-
restrained replication (Kapatai and Murray, 2007). Therefore, it 
can be concluded that EBV infects mostly germinal-centre and/
or memory B cells, and some naive B cells before they begin to 
replicate and proliferate (Kurth, 2000). HRS cells are believed 
to derive from germinal-centre B cells that evaded apoptosis by 
restricting their own gene expression and by receiving survival 
signals through stimulation of CD40 (Kanzler, et. al., 1996). EBV-
positive malignant cells provide proliferative and anti-apoptotic 
signals, assisting in survival and growth of the tumor (Kapatai 
and Murray, 2007). It remains unclear however, under which 
conditions EBV+ B cells enter germinal centres and how the 
EBV-gene expression in these cells is regulated, leading to the 
development of Hodgkin’s Lymphoma.
The EBV genome consists of a linear DNA molecule that en-
codes nearly 100 viral proteins. During the lytic state, these pro-
teins regulate the expression of viral genes causing viral DNA to 
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replicate. After infecting B cells, the linear EBV genome becomes 
circular, forming an episome. In these cells, the episome can rep-
licate independently of the host cell, regulated by the cell as 
part of the normal mechanism of memory B-cell homeostasis, 
thereby establishing a latent infection (Sarwari, et. al., 2016). The 
EBV viral genome is encased within a nucleocapsid surrounded 
by the viral envelope. Entry of EBV into B cells is initiated when 
the envelope glycoprotein, gp350, binds to the viral receptor 
on the surface of the B-cell called the CD21 molecule (Kojima, 
et. al., 2010). Infection of B lymphocytes with EBV results in 
persistent latent infection and immortalization of the cells to 
perpetual proliferation. 
Studies done using flow cytometry and PCR in biopsy speci-
mens demonstrated reactive B lymphocytes (Kojima, et. al., 2010). 
Based on these studies, it was observed that EBV infects naive B 
cells. This was derived from the fact that these are the only cells 
that were observed expressing all the latent EBV genes. The naïve 
EBV-infected B cells then undergo an expansion phase, thereby 
making use of normal B-cell differentiation pathways to establish 
a lifelong persistence in the B-cells. When tracking the primary 
infection of naive or memory B cells, Latent Membrane Protein 
1 (LMP1) and Latent Membrane Protein 2A (LMP2A) were both 
detected which suggests that they provide the signals for anti-
gen-independent replication in the germinal centre (Macsween 
and Crawford, 2003). In most HD cases the neoplastic cells are 
derived from B-cells as indicated by a sequence analysis of the im-
munoglobulin V region genes revealing mutations. In some cases, 
nonfunctional genes have been detected by stop codons in their 
sequence. Another study concluded that the site of persistence of 
EBV within the body must be the resting memory B cells based 
on the observation that “shedding of EBV from the oropharynx is 
abolished in patients treated with acyclovir whereas the number 
of EBV infected B cells in the circulation remains the same as 
before treatment” (Cohen, 2000) . 
In one important study, biopsy specimens of Hodgkin’s tumors 
revealed a 40-50% proportion of EBV positive tumors (Hjalgrim, 
et. al., 2003). Using southern blot hybridization viral RNAs (re-
ferred to as EBERs) and DNA fragments of EBV were detected 
in 20-25% of specimens. Likewise, patients with Hodgkin’s disease 
were often found to have higher titers of antibody to EBV pro-
teins before or with the onset of lymphoma, suggesting a correla-
tion between the two. Immunohistochemistry was performed on 
biopsy specimens from patients with HD. Using the immunop-
eroxidase technique, LMP-1-antibody was applied to the tumor 
section. Epstein-Barr virus early RNA transcripts (EBERs) were 
detected in tumor tissues via fluorescein-labeled oligonucleotides 
complementary to EBER (Alexander, et. al., 2000). The fragment 
was visualized under a microscope by tetramethyl rhodamine iso-
thiocyanate (TRITC), a bright orange-fluorescent dye. 
One study went so far as to suggest that EBV infection is 
actually the beginning of tumor development. EBV infection 
permanently induces B-cell activation, ultimately leading to un-
controllable cell division. EBV-positive HRS cells exhibit a type of 
virus latency and express different combinations of EBV nuclear 
and latent membrane proteins. In the first type, only EBNA-1 and 
EBER are expressed, while in the second, EBNA-1, LMP-1, LMP-2, 
and EBER are expressed. In the third pattern, all the latency genes 
are expressed. An additional pattern of latency was found in B 
cells obtained from the peripheral blood of patients with a past 
infection of EBV, in which only EBER and LMP-2, and in some cases, 
EBNA-1 have been detected (Mandage, et. al., 2017). Epstein-Barr 
virus nuclear antigen 1 (EBNA1) is a protein-encoding gene that is 
expressed in all EBV malignancies. EBV latent membrane protein 
1 (LMP1) is a gene which induces cellular activation and prolifer-
ation while inhibiting apoptosis through expression of the B-cell 
activation markers, CD23 and CD40 (Kapatai and Murray, 2007). 
EBV latent membrane protein 2 (LMP2A) expression enhances 
cell survival and inhibits normal B cell transduction. LMP2A does 
this by mimicking an activated B cell receptor (BCR), replacing 
the signals that are normally supplied to the B cells and suppress-
es cell immunity (Caldwell, et. al., 1998). Expression of LMP-2 in 
transgenic mice allowed B cells to survive even in the absence of 
normal B-cell–receptor signaling. It was also noticed that during 
primary infection, many EBV-positive cells appear to express all 
latent genes associated with viral-driven lymphoproliferative dis-
eases. (Steven, 1997).
BLF1 is a lytic cycle protein found to be involved at both initial 
and late stages of viral infection. It is involved in DNA replication, 
repair, and ultimately, immune avoidance. A recent study on EBV 
BPLF1-knockout mice demonstrated that the BPLF1-knockout 
mice were approximately 90% less likely to be infectious than 
wild-type (WT) mice. Without the BPLF1 there was a reduction 
in transformed human B cells. Overall, humanized mice infected 
with BPLF1-knockout virus survived longer than mice infected 
with the WT virus. Additionally, tumors were formed in 100% of 
mice infected with WT EBV but in only 25% of mice infected 
with BPLF1-KO virus (Whitehurst, et. al., 2015). These findings 
suggest that BRLF1 is required for activation of lytic replication 
and expression. Additionally, ten million cells were injected with 
either WT or BPLF1-knockout virus and after labeling with B- cell 
antibody, the total percentage of B-cells in each group was deter-
mined using flow cytometry. There was rarely B-cell outgrowth 
in cells infected with delta BPLF1 virus, suggesting that BPLF1 is 
necessary for immortalization of B-cells. This provides evidence 
that BPLF1 plays a role in B-cell transformation, and therefore 
contributes to EBV’s oncogenic role in cells. As of now, the mech-
anism by which BPLF1 inhibits these processes is still unknown.
Another EBV lytic gene expressed during infection of B cells 
is BALF1. This gene is known for its anti-apoptotic properties 
leading to B cell transformations. BARF1 is a secreted protein 
that blocks Colony Stimulating Factor 1 (CSF-1) signaling, func-
tioning as a trap to block the action of the cytokine. This helps 
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the virus evade the host’s immune system during acute EBV 
infection or reactivation of virus from latently infected cells 
(Ohashi, et. al., 2012).
Since the Epstein-Barr virus is associated with an increas-
ing number of diseases, including infectious mononucleosis 
and Hodgkin’s disease in both immunocompetent and immu-
nocompromised individuals (Yang, et. al., 2015), some research 
suggests that this correlation may be due to genetic factors.  The 
SH2D1A gene provides instructions for the synthesis of a pro-
tein called signaling lymphocyte activation molecule associated 
protein (SAP). SAP interacts with other proteins to activate 
signaling pathways that are involved in the control of immune 
cells. These cells are important in that they help control immune 
reactions and signal apoptosis. The SH2D1A gene is expressed 
primarily in T and NK cells as well as in some B-cells (Parolini, 
et. al., 2002).  Therefore, a defective gene causes an alteration 
of these lymphocytes which most likely results in the inability 
to control EBV infected cells. To test the possibility of SH2D1A 
gene involvement in the pathogenesis of Hodgkin’s disease, a 
SH2D1A gene analysis was studied in patients with a history 
of EBV and EBV- related diseases like Hodgkin’s lymphoma. A 
group of healthy patients was also analyzed to serve as the 
control group. Results showed an alteration in the 5′ region of 
the SH2D1A gene in the majority of patients with a diagnosis 
of mononucleosis, of which 25% went on to develop malignant 
B cell lymphomas.  This indicates that there may be a genetic 
correlation between EBV and HL.  
The SH2D1A gene is located on the X-chromosome, which 
may contribute to the fact that males are more prone to de-
velop Hodgkin’s Lymphoma after EBV (Robinson, 1976). Unlike 
females, males do not have another X chromosome to counter-
act the mutated gene. In one study 23 patients with HD, con-
sisting primarily of males, had their X-chromosomes analyzed. 
Analysis by reverse transcriptase polymerase chain reaction 
(RT-PCR) found EBV genome or protein in 16 of 23 tumor sam-
ples. The risk of contracting Hodgkin’s disease was found to be 
significantly increased in males who had a positive reaction to 
the Paul-Bunnell test, a heterophile antibody test that screens 
for IM.  (Rosdahl, et. al., 1974). Notably, anti-EBNA-1 antibody 
levels showed 43% heritability. 
In a study on transgenic mice, EBNA1 and LMP1 proved to play 
a key role in lymphoma development. EBNA1 is essential during 
cell division ensuring equal partitioning of a cell, while contribut-
ing to immortalization of cells by allowing for the maintenance of 
newly synthesized plasmids. The central part of EBNA1 consists 
of Gly-Ala repeats, which are believed to block the processing of 
proteins by proteasomes. This functions in inhibiting immune rec-
ognition and apoptosis of infected cells because viral proteins are 
normally broken down by proteasomes to peptides for recogni-
tion by cytotoxic T cells (Kojima, et. al., 2010). In turn, the infected 
cells that accumulate have oncogenic potential. During recovery 
from the acute phase, CD8+ T cells return to normal levels and 
antibodies develop against EBV nuclear antigen-1 (Balfour, et. al., 
2015). LMP-1 mimics CD40 and activates the nuclear factor-kap-
pa B, promoting cellular proliferation (Ok, et. al., 2015). LMP-1 
also induces BCL-2 and cyclin-dependent kinase 2, activating cell 
replication and inhibiting cell death. 
Conclusion 
Although an association has been identified, the pathogenetic 
role of EBV in these diseases is still unclear (Flavell, et. al., 2000). 
Likewise, the exact factors responsible for cancer development 
remains a matter of debate. Researchers are limited in their 
investigation of the relationship between viral infection and the 
development of cancer due to the lack of small animal mod-
els that can accurately reproduce the biology of EBV.  Yet over 
the past few years, some important advances have been made 
in understanding the biology of EBV and its role in the devel-
opment of EBV-associated lymphomas. The observation that a 
significant proportion of cases of HL contain the Epstein–Barr 
virus genome strongly suggests that the virus contributes to the 
development of the lymphoma. Significant progress has been 
made in understanding the functions of EBV-encoded genes in 
B cells (Sarwari, et. al., 2016) and viral protein functions. Several 
key issues remain to be clarified. 
Additionally, whereas EBV infection in tumors has been firmly 
established by several independent research groups, its associ-
ation remains controversial. Many still believe that it is by coin-
cidence, mainly due to the fact that the origin of Hodgkin’s can 
be regarded as heterogeneous because only half of the cases 
are known to be associated with EBV (Tamayose, et. al., 2004). 
Others maintain that Hodgkin lymphoma is a multi-factorial 
disease which depends on both biological and environmental 
factors and therefore, a specific causative agent cannot be pin-
pointed (Huang, et. al., 2012). 
There is no current approved treatment for EBV. Ongoing re-
search is currently trying to develop vaccines to prevent or treat 
these conditions. This is a difficult task due to a lack of an animal 
model to study the pathogenesis of the disease. It is further com-
plicated by the fact that the number of virus-infected cells in the 
body would amplify and establish latency before immune mech-
anisms develop. A future approach would be to synthetize ther-
apeutic vaccines designed to generate specific immune attacks 
for the latent virus. Adoptive immunotherapy and EBV-specific 
pharmacologic therapies offer promise for future treatment. 
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